ACST — Acasti Pharma Share Price
Last Trade - 00:00- CA$106.27m
- CA$29.57m
- CA$0.20m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Mar | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 0.2 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. It is developing a cardiovascular drug, CaPre (omega-3 phospholipid) for the treatment of hypertriglyceridemia. CaPre is a krill oil derived mixture containing polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). CaPre is designed to reduce triglycerides while also potentially providing beneficial effects on low-density lipoprotein (LDL) cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with severe hypertriglyceridemia.
Directors
- Roderick Carter
- Janelle D'Alvise PRE
- Brian Ford (72)
- Pierre Lemieux COO
- Brian Groch OTH
- Jean-Marie Canan (64)
- Donald Olds
- Last Annual
- March 31st, 2021
- Last Interim
- March 31st, 2021
- Incorporated
- February 6th, 2002
- Public Since
- March 31st, 2011
- No. of Shareholders
- 26
- No. of Employees
- 32
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 208,375,549
- Address
- 102-3009 boul. de la Concorde E, LAVAL, H7E 2B5
- Web
- https://www.acastipharma.com/
- Phone
- +1 4506864555
- Auditors
- KPMG LLP
Latest News for ACST
Upcoming events for ACST
Acasti Pharma Inc Annual Shareholders Meeting
Q2 2022 Acasti Pharma Inc Earnings Release
Similar to ACST
ADVANCED PROTEOME THERAPEUTICS ORD
TSX Venture Exchange
ALPHA COGNITION ORD
TSX Venture Exchange
ARCH BIOPARTNERS ORD
TSX Venture Exchange
BIOASIS TECHNOLOGIES ORD
TSX Venture Exchange
CEAPRO ORD
TSX Venture Exchange
FAQ
As of Today at 19:56 UTC, shares in Acasti Pharma are trading at CA$0.51. This share price information is delayed by 15 minutes.
Shares in Acasti Pharma last closed at CA$0.51 and the price had moved by -45.16% over the past 365 days. In terms of relative price strength the Acasti Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -55.56% over the past year.
The overall consensus recommendation for Acasti Pharma is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Acasti Pharma does not currently pay a dividend.
Acasti Pharma does not currently pay a dividend.
Acasti Pharma does not currently pay a dividend.
To buy shares in Acasti Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.51, shares in Acasti Pharma had a market capitalisation of CA$106.27m.
Here are the trading details for Acasti Pharma:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ACST
Based on an overall assessment of its quality, value and momentum Acasti Pharma is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Acasti Pharma is CA$0.15. That is 70.59% below the last closing price of CA$0.51.
Analysts covering Acasti Pharma currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.08 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acasti Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -60.61%.
As of the last closing price of CA$0.51, shares in Acasti Pharma were trading -21.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acasti Pharma.
Acasti Pharma's management team is headed by:
- Roderick Carter -
- Janelle D'Alvise - PRE
- Brian Ford -
- Pierre Lemieux - COO
- Brian Groch - OTH
- Jean-Marie Canan -
- Donald Olds -
We do not have data on Acasti Pharma's shareholders